Arabic Arabic English English French French German German
dark

aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response for ATYR1923 in Pulmonary Sarcoidosis

aTyr Pharma, Inc. today announced positive results from its Phase 1b/2a double-blind, placebo-controlled clinical trial of its lead therapeutic candidate, ATYR1923 Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

ClearDATA Partners with Interlace Health to Safeguard Data for Zero-Touch Patient Intake Solution

Next Post

Transgene Announces Upcoming Investor Meetings – Sep 13, 2021

Related Posts
Total
0
Share